DaVita Inc chief compliance officer Hearty sells $352k in stock

DaVita Inc. (DVA) reported mixed Q1 2025 results, surpassing adjusted EPS and revenue forecasts but falling short on adjusted EBIT, which led TD Cowen to lower its price target to $157 while maintaining a Hold rating. The company also upsized a senior notes offering to $1 billion for debt repayment and, despite lowering full-year volume expectations due to flu-related declines, reiterated its full-year guidance for EBIT, EPS, and free cash flow. Separately, DaVita's Chief Compliance Officer sold 2,351 shares worth $352,650 under a pre-arranged 10b5-1 trading plan.

Analysis

DaVita Inc. (DVA) presented a mixed operational and financial picture in its recent disclosures. The company reported first-quarter 2025 results that narrowly beat analyst expectations on the top and bottom lines, with revenue of $3.22 billion against a $3.20 billion forecast and adjusted EPS of $2.00 versus a $1.96 consensus. However, this performance was overshadowed by an underlying miss on adjusted EBIT, which prompted a cautious reaction from TD Cowen. The firm maintained its Hold rating but reduced its price target on DVA stock to $157 from $165. Compounding the concerns, DaVita revised its full-year 2025 volume expectations downward, citing flu-related census declines. Despite this significant operational headwind, management reiterated its full-year guidance for EBIT, EPS, and free cash flow, suggesting confidence in its ability to manage margins or find other efficiencies. On the capital structure front, the company successfully upsized a senior notes offering to $1 billion, with proceeds earmarked for repaying existing credit facilities. Separately, an insider sale by the Chief Compliance Officer of 2,351 shares for approximately $352,650 was disclosed, though its significance is mitigated as it was executed under a pre-arranged Rule 10b5-1 trading plan.

Key Decisions for Investors

• Investors should scrutinize DaVita's ability to meet its reiterated full-year EBIT and EPS guidance, as this now depends on offsetting the newly announced downward revision in patient volume expectations through margin improvement or other efficiencies.
• The price target reduction to $157 by TD Cowen provides a new valuation benchmark, reflecting analyst concern over the Q1 adjusted EBIT miss and creating a headwind for the stock's near-term performance.
• While the insider sale by the Chief Compliance Officer was pre-planned, it contributes to a mixed sentiment and should be considered alongside the fundamental challenges.
• The successful $1 billion debt offering to refinance existing credit facilities indicates market access and proactive balance sheet management, but investors should continue to monitor the company's leverage and interest expense.